Clinical trial
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate…
NCT00272038 · Oncology Specialists, S.C., Other · Completed
Key facts
| NCT number | NCT00272038 |
|---|---|
| Title | Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer |
| Official title | Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer |
| Lead sponsor | Oncology Specialists, S.C., Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Tarceva |
| Enrollment | 29 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Jan 4, 2006 |
| Last update posted | Jun 27, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: